Meagan Parrish
Lead Editor at Industry Dive
Lead Editor at PharmaVOICE
Senior editor for @industrydive, follower of the pharma world, proud mama, frequent flyer, occasional belly dancer.
Articles
-
1 week ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. Antibody-drug conjugates have become a “choose your own adventure” tool in pharma R&D. Due to their versatility, the therapies have proved themselves as a potent weapon against many oncology indications, AstraZeneca’s vice president and head of medical affairs for U.S. oncology told PharmaVoice last year. And the adventure more companies are choosing is solid tumors.
A startup with Theranos ties has another blood test in the works. This time, competition is waiting.
3 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. Diagnostics companies are having trouble escaping the shadow cast by Theranos, the blood testing biotech that failed in spectacular fashion. That challenge is already facing the new diagnostics startup Haemanthus — and it hasn’t even emerged from stealth.
-
3 weeks ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. AI-driven drug discovery has gotten much of the glory in pharma. Isomorphic Labs — which is leveraging an AI drug discovery platform based on Nobel Prize-winning AlphaFold software — pulled in the largest biotech investment haul this year to date with a $600 million fundraising round in March. And drug discovery is a prime focus for many of the highest valued AI companies working in pharma.
-
3 weeks ago |
finance.yahoo.com | Meagan Parrish
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. AI-driven drug discovery has gotten much of the glory in pharma. Isomorphic Labs — which is leveraging an AI drug discovery platform based on Nobel Prize-winning AlphaFold software — pulled in the largest biotech investment haul this year to date with a $600 million fundraising round in March.
-
1 month ago |
pharmavoice.com | Meagan Parrish
This audio is auto-generated. Please let us know if you have feedback. The days of animal testing in pharma could be dwindling as regulators push toward alternative models. This week, the NIH announced an initiative to adopt “innovative, human-based science” to limit the use of animals. “For decades, our biomedical research system has relied heavily on animal models. With this initiative, NIH is ushering in a new era of innovation,” NIH Director Dr. Jay Bhattacharya said in a statement.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 295
- Tweets
- 110
- DMs Open
- No
Recently caught up with SIGA Technologies, one of the sole producers of a monkeypox treatment, to find out how they're preparing for the potential of an ongoing outbreak. Here's my report: https://t.co/jFudmaQuQh
There are a host of reasons pharma could get its M&A groove back in 2022. Here's a look at some of the leading market factors on the pharma M&A scene. https://t.co/KsO1vfnZlE
For one of my first PharmaVoice articles, I picked a really interesting company to write about. With a novel platform and innovative vaccines, @vaxxinity is worth having on your pharma radar. https://t.co/sUmGTUcFPp